Here is a list of the most frequently asked questions about Biotech Supertrader and how it benefits investors all around the world.

1.  What is Biotech Supertrader exactly?
Biotech Supertrader is a trading service published by Hyperion Financial.  It’s written by noted analyst Robert Morris.  The service focuses solely on the explosive biotech sector and looks for stocks that have a very good chance at skyrocketing in the near term.

2.  How often is Biotech Supertrader published?
1-2 Biotech Supertrader recommendations are made each month, however, there's no set schedule as to when they are released.  This way, Robert has the flexibility to quickly alert his subscribers to time-sensitive opportunities.  Throughout each week, subscribers also get position and sector updates that review what's going on in the market as well as with current recommendations.  Sell alerts are also issued when Robert believes it's time to take profits and exit a position.

3.  What types of investments are recommended in Biotech Supertrader?
Robert only recommends individual stocks contained within the biotech sector.  Further, most of these stocks will trade for less than $10 per share, which is the optimum price for maximum appreciation potential in this sector.

There are no futures, options, or anything like that.  And you do not need an account with margin or any borrowed money.  Thus, a simple stock brokerage account is all you need to utilize the ideas found in Biotech Supertrader.

4.  Will the performance of Biotech Supertrader be affected by having too many subscribers?
Yes.  As with all of our trading services, once our subscribers' trades begin "influencing" the market, we will stop accepting new members and start a waiting list.  The initial number of members has been set at 750.

5.  Can those living in countries outside the US use your system?
Yes, as long as you are able to trade stocks on the US exchanges.  Most of the larger online brokers allow those living outside the US to open accounts and trade on the US exchanges.  We have subscribers from countries all around the world including the United States, Canada, Australia, England, New Zealand, and many more.

6.  What is the background of your editor Robert Morris?
Wall Street veteran and small company specialist Robert Morris is the editor of Biotech Supertrader.  Before coming to Hyperion Financial, Robert worked for a number of Wall Street firms such as Salomon Smith Barney, UBS, and Charles Schwab.

Before that, Robert used his law degree from George Washington University to advise small companies on a number of important issues.  It's this broad and unique perspective that gives Robert an edge in discovering tomorrow's 'next big thing', especially when it comes to biotech stocks- an area Robert has had tremendous success in.

7.  How much capital do I need to begin trading the recommendations?

There’s no specific amount of money that you need to dedicate to trading the recommendations.  You should determine what amount is appropriate based on your own personal money management and investment strategy.  The price of Robert's individual recommendations range from $1 a share all the way up to $20 a share or more- it really depends on the individual stock.

Remember, only use funds that you’ve set aside for speculative purposes.  Never use funds that you might need for food, clothing, the mortgage, rent, transportation, and other necessary living expenses.  Of course, be sure to seek the advice of your broker or financial advisor when determining if any particular investment is suitable for you.

8.  What’s the average holding period for your recommendations?

Biotech Supertrader is a relatively short-term trading service.  Most of our trades will last anywhere from 1 day to several months.  Sometimes we’ll have a big winner which may last a little longer.

9. What’s the performance of the recommendations?

We have a detailed performance page available only to our paid subscribers (because some of the positions are still open).  The performance page includes the buy price, the buy date, the current price, and return amount.

10.  What markets are the recommended biotech stocks traded on?

All of our picks trade on the NYSE, NYSE Arca, Pink Sheets, or NASDAQ.  As long as you have a broker with access to these markets, you’ll be able to trade our recommendations.

For more information, click here.

11.  What broker should I use to trade your biotech stock recommendations?

The stocks recommended by Biotech Supertrader can be traded through just about any brokerage firm, online or off.  We have no affiliation with any broker or firm.  We suggest you contact several brokers to find one that best meets your needs.

12.  If I sign up today, when will I receive my first recommendation or position update email?

Occasionally, it can take a few days to get your subscription into our system.  But in most cases, you'll have access to the most recent recommendation, position updates, and the current portfolio the moment you subscribe.

13.  How much does Biotech Supertrader cost?

Biotech Supertrader costs just $197 per quarter.  That means we’ll bill your credit card every 3 months until you tell us to stop.  That way you’ll get uninterrupted service for as long as you want it (and you’re using the service).

The quarterly membership fee includes the timely recommendations, position updates, sell alerts, and access to our members-only website.  Additionally, you will receive a comprehensive Operating Manual and Biotech 101 report to help you quickly get up-to-speed on the dynamic biotech sector and how to best use Biotech Supertrader.

14.  How do I cancel my subscription to Biotech Supertrader?

If you ever want to cancel your subscription, just send an email to notifying us of your wish to do so.  Your subscription will then run until the end of the current quarter, at which time it will be cancelled.  You will not be rebilled once your quarterly subscription ends.  Please note, we do not offer refunds on our subscriptions.

15.  Will you respond to questions and comments about the market, the stock recommendations, investment strategy and other similar topics?

Unfortunately, due to US Securities Laws and Regulations, we are not permitted to respond personally to individual questions about the market, individual investments or the investment strategy.  However, questions we receive via email are forwarded to the editor for possible inclusion in future monthly issues and portfolio update emails.

For more information, click here.